Autologous Noncryopreserved Hematopoietic Stem Cell Transplant With CEAM as a Modified Conditioning Regimen in Patients With Hodgkin Lymphoma: A Single-center Experience With a New Protocol

Abstract

Conclusions: These data demonstrate the safety and feasibility of BEAM-like regimen as a new and modified regimen; longer follow-up is required to evaluate fully efficacy and long-term safety of our method.

Lymphomas

“…Regimens avoiding BCNU by using high-dose melphalan or melphalan with etoposide and cyclophosphamide have been reported Guilcher et al 2012 ;Schutt et al 2007 ). Modifi ed BEAM regimens have substituted alternative chloroethylnitrosureas for BCNU, including fotemustine and lomustine (Musso et al 2010 ;Ramzi et al 2012 ), although neither regimen has supplanted traditional BEAM.…”

EAM as a New Conditioning Regimen for Lymphoma Patients Undergoing Autologous Progenitor Cell Transplantation

“…In lymphoma, the protocols used were of more different type: CBV, BEAM [3], BEAC [4] CEAM [5], FEAM [6] or LACE [7]. CBV and BEAM are the two most frequently used regimens for patients with lymphoma undergoing autologous progenitor cells transplantation (APCT).…”

Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose

“…5 In the same way, higher doses of lomustine have been used in other chemotherapy schemes because of its lower pulmonary toxicity when compared with carmustine. Pulmonary toxicity usually occurs with lomustine when doses higher than 1000 mg/m 2 are used.…”

“…2,3 However, when it is associated with a combination of etoposide, ara-C and cyclophosphamide, or etoposide, ara-C and melphalan, a dose of 200 mg/m 2 has been used. [4][5][6] Although the success of auto-HSCT depends on several variables, the lower the toxicity and the duration of neutropenia the smaller the treatment-related mortality.…”